Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/12912943

Clin. Cancer Res. 2003 Aug 1 9 8 2965-72

Download in:

View as

Triples

General Info

PMID
12912943